Effective: January 13, 2017
The Drug Enforcement Agency (DEA), has proposed that the extract of CBD hemp oil, that is ‘‘an extract containing one or more cannabinoids that has been derived from any plant of the genus Cannabis, other than the separated resin (whether crude or purified) obtained from the plant.’’ Cannabis extracts, including cannabidiol (CBD), will continue to be treated as Schedule I controlled substances.
According to the DEA, "Schedule I drugs, substances, or chemicals are defined as drugs with no currently accepted medical use and a high potential for abuse,"
Interest in the potential therapeutic effects of CBD has been growing rapidly, partially in response to media attention surrounding the use of CBD oil in young children with intractable seizure disorders including Dravet syndrome and Lennox-Gastaut syndrome. In addition to epilepsy, the therapeutic potential of CBD is currently being explored for a number of indications including anxiety disorders, substance use disorders, schizophrenia, cancer, pain, inflammatory diseases and others.
Researchers have evaluated that CBD has a wide range of therapeutic effects, including but not limited to, anti-seizure, antioxidant, neuroprotective, anti-inflammatory, analgesic, anti-tumor, anti-psychotic and anti-anxiety properties.
This feed contains research, news, information, observations, and ideas at the level of self in an effort to address health concepts.